Gain-of-function mutations in PIK3CA (encoding p110α) that activate the PI3K cascade are highly prevalent in a number of malignancies, including up to 40% of breast cancer patients [49] and as many as 53% of endometrial cancer patients [50]. Here, PIK3CA is linked to breast carcinoma.